Biotech | February 25, 2022
USFDA grants Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis therapy
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases